Related Experiment Video

Updated: Sep 27, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner

Dawei Wang1, Xiaojing Wang1, Baoxing Huang1

  • 1Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Andrologia
|April 12, 2022
PubMed

Insights

Methyltransferase-like 3 (METTL3) promotes prostate cancer progression by regulating m6A modification of pre-miR-182. Inhibiting METTL3 may offer a new targeted therapy for prostate cancer (PCa).

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Methyltransferase-like 3 (METTL3) is involved in RNA modification and cancer progression.
  • METTL3's role in prostate cancer (PCa) via N6-methyladenosine (m6A) modification of non-coding RNA remains unclear.

Purpose of the Study:

  • To investigate the role of METTL3 in prostate cancer (PCa) development.
  • To elucidate the mechanism by which METTL3 promotes PCa, focusing on m6A modification of non-coding RNAs.

Main Methods:

  • Quantitative reverse transcription PCR (qRT-PCR) and Western blot to analyze METTL3 expression.
  • Cell proliferation, migration, invasion, and tumorigenesis assays (CCK-8, colony formation, wound-healing, Transwell, and nude mice models).
  • N6-methyladenosine (m6A) RNA immunoprecipitation (MeRIP) and co-immunoprecipitation assays to determine molecular interactions and RNA modification.

Main Results:

  • METTL3 is highly expressed in PCa tissues and cells.
  • METTL3 knockdown inhibited PCa cell proliferation, migration, invasion, and tumorigenesis; conversely, overexpression promoted these processes.
  • METTL3 upregulates m6A levels, interacts with DGCR8, and regulates the maturation of pre-miR-182, thereby promoting PCa progression.

Conclusions:

  • METTL3 promotes prostate cancer (PCa) progression through the m6A modification and maturation of pre-miR-182.
  • METTL3 is a potential therapeutic target for PCa treatment.
Keywords:
METTL3m6AmiR-182prostate cancer

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K